CADL

Candel Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website candeltx.com
Employees(FY) 76
ISIN US1374041093

Performance

+1.27%

-10.06%

+32.16%

+20.78%

-17.63%

YTD

+450.0%

Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.

Advanced Technical Analysis

Technical Analysis of CADL 2025-01-31

The stock indicators suggest a generally bullish sentiment, with the Moving Average Score at 63 and the Technical Score at 62 indicating positive momentum, while the Oscillators Score remains neutral at 50. This combination reflects a favorable outlook for the stock, driven primarily by strong moving averages and technical indicators.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CADL

Stock Rank

Recent News & Updates

2025-01-12 19:00
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025(Globenewswire)
2025-01-08 12:44
After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win(Yahoo Finance)
2024-12-19 00:44
Hedge Fund and Insider Trading News: Simon Sadler, Stanley Druckenmiller, Warren Buffett, Caxton Associates, Millennium Management, Saba Capital, Candel Therapeutics Inc (CADL), NVIDIA Corp (NVDA), and More(Insidermonkey)
2024-12-16 03:01
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares(Globenewswire)
2024-12-12 10:00
Candel Therapeutics Announces Pricing of Public Offering(Globenewswire)
2024-12-12 03:51
Candel Therapeutics Announces $80 Million Proposed Public Offering(Globenewswire)
2024-12-11 03:09
Candel Skyrockets 68% On A Potential First-In-20-Years Cancer Drug(Yahoo Finance)
2024-12-11 00:07
Candel Therapeutics Prostate Cancer Therapy Shows Promise(Yahoo Finance)
2024-12-11 00:07
Candel Therapeutics Prostate Cancer Therapy Shows Promise(Yahoo Finance)
2024-12-10 22:54
Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug(Yahoo Finance)
2024-12-10 21:32
Candel Therapeutics stock up 172% after Phase III prostate cancer success(Yahoo Finance)
2024-12-10 20:19
Candel Therapeutics Stock Surges Over 100% - Here's Why(Yahoo Finance)
2024-12-10 18:00
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival(Globenewswire)
2024-11-13 19:00
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights(Globenewswire)
2024-11-06 19:00
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024(Globenewswire)
2024-11-04 20:00
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma(Globenewswire)
2024-10-28 20:59
Candel Therapeutics Advances in Cancer Treatment Trials(Yahoo Finance)
2024-10-27 20:00
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)(Globenewswire)
2024-10-03 21:00
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting(Globenewswire)
2024-09-03 20:00
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors(Globenewswire)
2024-09-02 20:00
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-12 20:00
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights(Globenewswire)
2024-08-12 04:37
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates(Prnewswire)
2024-06-17 20:00
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference(Globenewswire)
2024-06-13 20:30
Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments(Newsdirect)
2024-06-13 19:15
7 A-Rated Biotech Stocks Worth Betting on in June(Investorplace)
2024-06-11 22:22
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments(Prnewswire)
2024-06-10 20:00
Candel Therapeutics to Join Russell 3000 Index(Globenewswire)
2024-06-06 20:30
Candel Therapeutics' (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers(Newsdirect)
2024-06-02 20:30
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer(Newsdirect)

Page 1 of 6

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.